Literature DB >> 22126294

DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology.

Jian Tajbakhsh1.   

Abstract

Targeting chromatin and its basic components through epigenetic drug therapy has become an increased focus in the treatment of complex diseases. This boost calls for the implementation of high-throughput cell-based assays that exploit the increasing knowledge about epigenetic mechanisms and their interventions for genotoxicity testing of epigenetic drugs. 3D quantitative DNA methylation imaging is a novel approach for detecting drug-induced DNA demethylation and concurrent heterochromatin decondensation/reorganization in cells through the analysis of differential nuclear distribution patterns of methylcytosine and gDNA visualized by fluorescence and processed by machine-learning algorithms. Utilizing 3D DNA methylation patterns is a powerful precursor to a series of fully automatable assays that employ chromatin structure and higher organization as novel pharmacodynamic biomarkers for various epigenetic drug actions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22126294      PMCID: PMC3250213          DOI: 10.2217/epi.11.101

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  66 in total

1.  Chromosome Conformation Capture Carbon Copy (5C): a massively parallel solution for mapping interactions between genomic elements.

Authors:  Josée Dostie; Todd A Richmond; Ramy A Arnaout; Rebecca R Selzer; William L Lee; Tracey A Honan; Eric D Rubio; Anton Krumm; Justin Lamb; Chad Nusbaum; Roland D Green; Job Dekker
Journal:  Genome Res       Date:  2006-09-05       Impact factor: 9.043

Review 2.  Phenotypic plasticity and the epigenetics of human disease.

Authors:  Andrew P Feinberg
Journal:  Nature       Date:  2007-05-24       Impact factor: 49.962

Review 3.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

4.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

Authors:  Steven D Gore; Stephen Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael Carducci; Michael Grever; Oliver Galm; Tianna Dauses; Judith E Karp; Michelle A Rudek; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George Dover; Abbie Mays; James Zwiebel; Anthony Murgo; Li-Jun Weng; James G Herman
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

5.  The micronucleus test.

Authors:  W Schmid
Journal:  Mutat Res       Date:  1975-02       Impact factor: 2.433

6.  Automated quantification of DNA demethylation effects in cells via 3D mapping of nuclear signatures and population homogeneity assessment.

Authors:  Arkadiusz Gertych; Kolja A Wawrowsky; Erik Lindsley; Eugene Vishnevsky; Daniel L Farkas; Jian Tajbakhsh
Journal:  Cytometry A       Date:  2009-07       Impact factor: 4.355

7.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2007-06-27       Impact factor: 22.113

Review 8.  Cancer as a manifestation of aberrant chromatin structure.

Authors:  Malcolm V Brock; James G Herman; Stephen B Baylin
Journal:  Cancer J       Date:  2007 Jan-Feb       Impact factor: 3.360

9.  Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines.

Authors:  Sabine Hagemann; Oliver Heil; Frank Lyko; Bodo Brueckner
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

10.  DNA methylation affects nuclear organization, histone modifications, and linker histone binding but not chromatin compaction.

Authors:  Nick Gilbert; Inga Thomson; Shelagh Boyle; James Allan; Bernard Ramsahoye; Wendy A Bickmore
Journal:  J Cell Biol       Date:  2007-05-07       Impact factor: 10.539

View more
  4 in total

Review 1.  The various aspects of genetic and epigenetic toxicology: testing methods and clinical applications.

Authors:  Ning Ren; Manar Atyah; Wan-Yong Chen; Chen-Hao Zhou
Journal:  J Transl Med       Date:  2017-05-22       Impact factor: 5.531

2.  Oregonin from Alnus incana bark affects DNA methyltransferases expression and mitochondrial DNA copies in mouse embryonic fibroblasts.

Authors:  Jelena Krasilnikova; Liga Lauberte; Elena Stoyanova; Desislava Abadjieva; Mihail Chervenkov; Mattia Mori; Elisa De Paolis; Vanya Mladenova; Galina Telysheva; Bruno Botta; Elena Kistanova
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

3.  3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models.

Authors:  Arkadiusz Gertych; Jin Ho Oh; Kolja A Wawrowsky; Daniel J Weisenberger; Jian Tajbakhsh
Journal:  BMC Pharmacol Toxicol       Date:  2013-02-11       Impact factor: 2.483

4.  Nuclear DNA methylation and chromatin condensation phenotypes are distinct between normally proliferating/aging, rapidly growing/immortal, and senescent cells.

Authors:  Jin Ho Oh; Arkadiusz Gertych; Jian Tajbakhsh
Journal:  Oncotarget       Date:  2013-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.